DAIC

MAY 6, 2024

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Circulation: Cardiovascular Quality & Outcomes

MARCH 26, 2025

BACKGROUND:Remote health management programs utilizing evidence-based algorithm-driven virtual care solutions for chronic disease management offer a novel approach to addressing implementation gaps for conditions such as hypertension. Most patient participants were male (n=12) and identified their race and ethnicity as White (n=15).

Hypertension 40

Hypertension Blood Pressure Chronic Disease Innovation 40

DAIC

FEBRUARY 12, 2024

In November, 2022, the company launched its new Barostim NEO2 IPG. CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases.

Heart Failure 104

Heart Failure Hospital Quality of Life Heart Attack 104

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

FEBRUARY 12, 2024

In November, 2022, the company launched its new Barostim NEO2 IPG. CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases.

Heart Failure 52

Heart Failure Hospital Quality of Life Heart Attack 52

DAIC

FEBRUARY 7, 2024

This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022. The framework outlines opportunities for the broader integration of the technology into the workflow for screening and diagnosing cardiovascular disease, using AFib and Hypertension as examples.

Technology 116

Technology Cardiovascular Disease Best Practices AFIB 116

DAIC

APRIL 1, 2024

“We are witnessing a paradigm shift in how valvular heart diseases are diagnosed and treated,” said Partho Sengupta , Henry Rutgers Professor of Cardiology and chief of the Division of Cardiovascular Disease and Hypertension at Rutgers Robert Wood Johnson Medical School. Is There Medication for Valvular Heart Disease?

Technology 105

Technology Heart Disease Innovation Ultrasound 105